1-(5-methyl-1,2,4-oxadiazol-3-yl)piperazine monohydrochloride | 1440955-11-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(5-methyl-1,2,4-oxadiazol-3-yl)piperazine monohydrochloride
• 英文别名: 1-(5-methyl-(1,2,4)oxadiazol-3-yl)-piperazine hydrochloride；5-methyl-3-piperazin-1-yl-1,2,4-oxadiazole hydrochloride；1-(5-Methyl-1,2,4-oxadiazol-3-yl)piperazine hydrochloride；5-methyl-3-piperazin-1-yl-1,2,4-oxadiazole;hydrochloride
• CAS: 1440955-11-2
• 化学式: C₇H₁₂N₄O*ClH
• 分子量: 204.659
• InChiKey: KUOKMUKOOXRLQJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.21
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  54.2
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (3S,5S)-1-(tert-butoxycarbonyl)-5-(1-pyrrolidinylcarbonyl)-3-pyrrolidinecarboxylic acid 、 1-(5-methyl-1,2,4-oxadiazol-3-yl)piperazine monohydrochloride 在 N-甲基吗啉 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 19.0h， 以82%的产率得到tert-butyl (2S,4S)-4-{[4-(5-methyl-1,2,4-oxadiazol-3-yl)-1-piperazinyl]carbonyl}-2-(1-pyrrolidinylcarbonyl)-1-pyrrolidinecarboxylate
  参考文献：
  名称：

  Design and synthesis of DPP-IV inhibitors lacking the electrophilic nitrile group

  摘要：

  A series of (4 beta-substituted)-L-prolylpyrrolidine analogs lacking the electrophilic nitrile function were synthesized and their dipeptidyl peptidase IV (DPP-IV) inhibitory activity and duration of ex vivo activity were evaluated. Structural optimization of a N-(3-phenyl-1,2,4-thiadiazol-5-yl) piperazine analog 8, which was found by high-speed analog synthesis, was carried out to improve the potency and duration of action. A representative compound 26 was evaluated to assess its effect on the plasma glucose level after the oGTT (oral glucose tolerance test) in normal rats. Structure-activity relationships (SAR) are also presented. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.11.031
• 作为产物：
  描述：

  tert-butyl 4-(N-hydroxycarbamimidoyl)piperazine-1-carboxylate 在 吡啶 、 盐酸 作用下， 以 1,4-二氧六环 、 乙醚 为溶剂， 反应 3.0h， 生成 1-(5-methyl-1,2,4-oxadiazol-3-yl)piperazine monohydrochloride
  参考文献：
  名称：

  [EN] HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR USE IN THE TREATMENT HELMINTH INFECTION
  [FR] COMPOSÉS HÉTÉROARYLES À UNITÉ DE PONTAGE CYCLIQUE UTILISÉS DANS LE TRAITEMENT D'INFECTIONS HELMINTHIQUES

  摘要：

  本发明涉及某些杂环烯基化合物，用作药物，更具体地用作治疗动物的药物。该药物可用于治疗蠕虫感染和由蠕虫感染引起的寄生虫病的治疗。本发明还涉及利用这些化合物制备药物和治疗方法，包括将这些化合物给予需要治疗的动物。本发明还涉及包含这些化合物的药物组合物和配套工具。

  公开号：

  WO2013144180A1

文献信息

• NOVEL COMPOUNDS
  申请人：GRAUERT Matthias

  公开号：US20130143870A1

  公开（公告）日：2013-06-06

  This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R 1 , R 2 , R 3 have meanings given in the description.

  这项发明涉及公式I的化合物，它们作为mGlu5受体活性的正向变构调节剂的用途，含有这些化合物的药物组合物，以及将其用作治疗和/或预防与谷氨酸功能障碍相关的神经和精神障碍，如精神分裂症或认知功能下降，如痴呆症或认知障碍的药剂的方法。A、B、X、R1、R2、R3在描述中给出了它们的含义。
• Compounds
  申请人：Grauert Matthias

  公开号：US08741892B2

  公开（公告）日：2014-06-03

  This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

  本发明涉及I式化合物，其用作mGlu5受体活性的正向变构调节剂，含有该化合物的制药组合物，以及将其用作治疗和/或预防与谷氨酸功能失调有关的神经和精神障碍，如精神分裂症或认知衰退，如痴呆或认知障碍的药物的方法。其中，A、B、X、R1、R2、R3在描述中给出了其含义。
• HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT
  申请人：Intervet Inc.

  公开号：US20150080365A1

  公开（公告）日：2015-03-19

  This invention relates to certain heteroaryl compounds for use as medicaments, more specifically as medicaments for treating animals. The medicament can be used for the treatment of helminth infections and the treatment of parasitosis caused by helminth infections. This invention also relates to uses of the compounds to make medicaments and treatments comprising the administration of the compounds to animals in need of the treatments. This invention also relates to pharmaceutical compositions and kits comprising the compounds.

  本发明涉及某些杂环芳基化合物，用作药物，更具体地用作治疗动物的药物。该药物可用于治疗蠕虫感染和由蠕虫感染引起的寄生虫病的治疗。本发明还涉及使用这些化合物制造药物和治疗，包括将这些化合物用于需要治疗的动物的给药。本发明还涉及包含这些化合物的制药组合物和套装。
• Heteroaryl compounds with cyclic bridging unit
  申请人：Intervet Inc.

  公开号：US09260441B2

  公开（公告）日：2016-02-16

  This invention relates to certain heteroaryl compounds for use as medicaments, more specifically as medicaments for treating animals. The medicament can be used for the treatment of helminth infections and the treatment of parasitosis caused by helminth infections. This invention also relates to uses of the compounds to make medicaments and treatments comprising the administration of the compounds to animals in need of the treatments. This invention also relates to pharmaceutical compositions and kits comprising the compounds.

  本发明涉及某些杂环芳基化合物，用作药物，更具体地用作治疗动物的药物。该药物可用于治疗蠕虫感染和由蠕虫感染引起的寄生虫病的治疗。本发明还涉及利用这些化合物制备药物和治疗方案，包括将这些化合物给需要治疗的动物进行治疗。本发明还涉及包含这些化合物的制药组合物和试剂盒。
• SUBSTITUTED PYRAZOLES AS MGLU5 RECEPTOR MODULATORS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2788086B1

  公开（公告）日：2016-10-12